Your session is about to expire
← Back to Search
Duvelisib for Peripheral T-Cell Lymphoma (PRIMO Trial)
PRIMO Trial Summary
This trial is testing a new cancer drug for patients with a certain type of T cell lymphoma who have relapsed or who haven't responded to other treatments.
PRIMO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPRIMO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 319 Patients • NCT02004522PRIMO Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you detail other research investigations that have used Duvelisib?
"In 2014, the Dana Farber Cancer Institute initiated research into duvelisib. Thus far, 13 studies have been concluded and 16 are still in progress - with many located within Chicago's metropolitan area."
What has Duvelisib been employed to address medically?
"Duvelisib has been proven to be efficacious against refractory, relapsed small lymphocytic lymphoma and other conditions including therapeutic procedure, two prior therapies, and refractory anemias."
Are there numerous healthcare facilities implementing this experiment in Canada?
"This trial is being conducted in 19 locations, including Chicago, Stony Brook and Irvine. To minimize travel time for participants, it is prudent to select the closest site near you."
What is the current enrollment of participants in this experiment?
"This clinical trial has reached its recruitment target and is not currently open to new candidates. It was initially posted on February 22nd 2018, with the last update being May 3rd 2022. Alternately, there are 1731 trials regarding lymphoma and 16 studies for Duvelisib that are actively recruiting patients as of now."
Does this scientific experiment require more participants?
"Unfortunately, no more candidates may join this trial as it was last updated on May 3rd 2022. If you are still hoping to find a study that matches your needs, 1731 trials for lymphoma and 16 studies involving Duvelisib are currently accepting patients."
Has Duvelisib received governmental authorization to be used in practice?
"According to our experts at Power, Duvelisib's safety can be assessed as a 2. This is due to it being in the Phase 2 of this clinical trial process, meaning there has been some data collected that supports its security but none indicating effectiveness."
Does this research venture introduce a new methodology?
"Secura Bio, Inc. kicked off the first Duvelisib clinical trial in 2014 with 32 patients. This study was followed by Phase 1 & 2 approval and today it is being tested across 68 cities in 8 nations - there are 16 active trials for this medication."
Share this study with friends
Copy Link
Messenger